IDT Australia (ASX:IDT) Pretax Margin %: -13.56% (As of Dec. 2025)


What is IDT Australia Pretax Margin %?

IDT Australia ASX:IDT Pretax Margin % is -13.56% as of Dec. 2025. The stock has 6 warning signs investors should review. Among 955 Drug Manufacturers companies, IDT Australia ranks worse than 84.08% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. IDT Australia's Pre-Tax Income for the six months ended in Dec. 2025 was A$-1.32 Mil. IDT Australia's Revenue for the six months ended in Dec. 2025 was A$9.72 Mil. Therefore, IDT Australia's pretax margin for the quarter that ended in Dec. 2025 was -13.56%.

The historical rank and industry rank for IDT Australia's Pretax Margin % or its related term are showing as below:

ASX:IDT' s Pretax Margin % Range Over the Past 10 Years
Min: -159.72   Med: -43.95   Max: 6.03
Current: -32.67


ASX:IDT's Pretax Margin % is ranked worse than
84.08% of 955 companies
in the Drug Manufacturers industry
Industry Median: 7.28 vs ASX:IDT: -32.67

IDT Australia  (ASX:IDT) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


IDT Australia Pretax Margin % Related Terms


IDT Australia Pretax Margin % Historical Data

* Premium members only.

The historical data trend for IDT Australia's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IDT Australia Pretax Margin % Chart

IDT Australia Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.03 -15.50 -140.97 -45.93 -41.96

IDT Australia Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -70.47 -27.17 -31.94 -53.24 -13.56

ASX:IDT vs ZTS: Pretax Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, IDT Australia's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IDT Australia Pretax Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, IDT Australia's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where IDT Australia's Pretax Margin % falls into.



IDT Australia Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

IDT Australia's Pretax Margin for the fiscal year that ended in Jun. 2025 is calculated as

Pretax Margin=Pre-Tax Income (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-8.063/19.217
=-41.96 %

IDT Australia's Pretax Margin for the quarter that ended in Dec. 2025 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-1.318/9.723
=-13.56 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of -13.56% mean?
IDT Australia (ASX:IDT) has a Pretax Margin % of -13.56% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on IDT Australia and its competitors. According to the industry distribution chart, IDT Australia ranks #803 out of 955 companies in the Drug Manufacturers industry, placing it in the top 84.1%.
Is IDT Australia's Pretax Margin % too high?
IDT Australia's current Pretax Margin % is -13.56%. Based on the distribution chart, IDT Australia ranks #803 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does IDT Australia's Pretax Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, IDT Australia ranks #803 out of 955 companies for Pretax Margin %. This places IDT Australia in the lower half of its industry. The industry median Pretax Margin % is 7.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on IDT Australia and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDT Australia's current Pretax Margin % is -13.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDT Australia stock overvalued right now?
Based on GuruFocus' analysis, IDT Australia (ASX:IDT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.17, compared to a current price of A$0.03 — trading 80.6% below its estimated fair value. The current Pretax Margin % is -13.56%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For IDT Australia (ASX:IDT), the current Pretax Margin % is -13.56% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

IDT Australia Business Description

Address 45 Wadhurst Drive, Boronia, Melbourne, VIC, AUS, 3155
IDT Australia Ltd produces, develops, and supplies pharmaceutical products. It is engaged in the provision of research and development and other technical services for the pharmaceutical and allied industries. The company is involved in the manufacture of Active Pharmaceutical Ingredients (API) and Finished Dose Forms (FDF), microbiological and analytical testing, clinical packaging, and pharmacy services. The company operates in Australia, Asia, Europe, and the USA.